158 related articles for article (PubMed ID: 35986542)
1. Anti-Tubercular Activity of Pyrazinamide Conjugates: Synthesis and Structure-Activity Relationship Studies.
Wahan SK; Sharma S; Chawla PA
Mini Rev Med Chem; 2023; 23(6):700-718. PubMed ID: 35986542
[TBL] [Abstract][Full Text] [Related]
2. [Prevalence and transmission of pyrazinamide-resistant
Liu BB; Hu PL; Chen ZH; Yi SL; Zhang XP; Tan YH
Zhonghua Jie He He Hu Xi Za Zhi; 2022 Jul; 45(7):677-685. PubMed ID: 35768376
[No Abstract] [Full Text] [Related]
3. Recent updates on drug resistance in Mycobacterium tuberculosis.
Singh R; Dwivedi SP; Gaharwar US; Meena R; Rajamani P; Prasad T
J Appl Microbiol; 2020 Jun; 128(6):1547-1567. PubMed ID: 31595643
[TBL] [Abstract][Full Text] [Related]
4. Computational discovery of potent drugs to improve the treatment of pyrazinamide resistant Mycobacterium tuberculosis mutants.
Jagadeb M; Rath SN; Sonawane A
J Cell Biochem; 2018 Sep; 119(9):7328-7338. PubMed ID: 29761826
[TBL] [Abstract][Full Text] [Related]
5. Increasing resistance of M. tuberculosis to anti-TB drugs in Saudi Arabia.
Khan MY; Kinsara AJ; Osoba AO; Wali S; Samman Y; Memish Z
Int J Antimicrob Agents; 2001 May; 17(5):415-8. PubMed ID: 11337231
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China.
Pang Y; Zhu D; Zheng H; Shen J; Hu Y; Liu J; Zhao Y
BMC Infect Dis; 2017 Nov; 17(1):711. PubMed ID: 29110640
[TBL] [Abstract][Full Text] [Related]
7. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in the research of heterocyclic compounds as antitubercular agents.
Yan M; Ma S
ChemMedChem; 2012 Dec; 7(12):2063-75. PubMed ID: 23042656
[TBL] [Abstract][Full Text] [Related]
9. Pyrazinamide resistance-conferring mutations in pncA and the transmission of multidrug resistant TB in Georgia.
Sengstake S; Bergval IL; Schuitema AR; de Beer JL; Phelan J; de Zwaan R; Clark TG; van Soolingen D; Anthony RM
BMC Infect Dis; 2017 Jul; 17(1):491. PubMed ID: 28697808
[TBL] [Abstract][Full Text] [Related]
10. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.
Chang KC; Leung CC; Yew WW; Leung EC; Leung WM; Tam CM; Zhang Y
Antimicrob Agents Chemother; 2012 Nov; 56(11):5465-75. PubMed ID: 22869570
[TBL] [Abstract][Full Text] [Related]
11. Coumarin hybrid derivatives as promising leads to treat tuberculosis: Recent developments and critical aspects of structural design to exhibit anti-tubercular activity.
Reddy DS; Kongot M; Kumar A
Tuberculosis (Edinb); 2021 Mar; 127():102050. PubMed ID: 33540334
[TBL] [Abstract][Full Text] [Related]
12. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
13. Pyrazinamide resistance among drug-resistant Mycobacterium tuberculosis isolates at a referral hospital.
Arora J; Sidiq Z; Visalakshi P; Bhalla M; Behera D; Myneedu VP
Diagn Microbiol Infect Dis; 2013 Dec; 77(4):380-1. PubMed ID: 24075630
[No Abstract] [Full Text] [Related]
14. The Bewildering Antitubercular Action of Pyrazinamide.
Lamont EA; Dillon NA; Baughn AD
Microbiol Mol Biol Rev; 2020 May; 84(2):. PubMed ID: 32132245
[TBL] [Abstract][Full Text] [Related]
15. Reactive dirty fragments: implications for tuberculosis drug discovery.
Gopal P; Dick T
Curr Opin Microbiol; 2014 Oct; 21():7-12. PubMed ID: 25078318
[TBL] [Abstract][Full Text] [Related]
16. [Trends in tuberculosis treatment duration].
Veziris N; Aubry A; Truffot-Pernot C
Presse Med; 2006 Nov; 35(11 Pt 2):1758-1764. PubMed ID: 17086138
[TBL] [Abstract][Full Text] [Related]
17. [Investigation of pncA, rpsA and panD Gene Mutations Associated with Resistance in Pyrazinamide-Resistant Mycobacterium tuberculosis Isolates and Spoligotyping].
Özgür D; Tezcan Ülger S; Kayar MB; Biçmen C; Aslantürk A; Ülger M; Aslan G
Mikrobiyol Bul; 2022 Apr; 56(2):191-205. PubMed ID: 35477224
[TBL] [Abstract][Full Text] [Related]
18. Isoniazid derivatives and their anti-tubercular activity.
Hu YQ; Zhang S; Zhao F; Gao C; Feng LS; Lv ZS; Xu Z; Wu X
Eur J Med Chem; 2017 Jun; 133():255-267. PubMed ID: 28390957
[TBL] [Abstract][Full Text] [Related]
19. Pyrazinamide resistance in rifampicin discordant tuberculosis.
Mvelase NR; Singh R; Swe Swe-Han K; Mlisana KP
PLoS One; 2022; 17(9):e0274688. PubMed ID: 36129921
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
